OA
VRTX icon

Oracle Alpha’s Vertex Pharmaceuticals VRTX Stock Holding History

Oracle Alpha’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$479K Buy
1,147
+277
+32% +$117K 0.86% 23
2023
Q4 		$354K Buy
+870
New +$321K 0.46% 74

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Oracle Alpha's VRTX Position: Q1 2024 in Review

Oracle Alpha increased its Vertex Pharmaceuticals (VRTX) stake by 32% in Q1 2024, buying an estimated $117K and bringing the position to 1,147 shares worth $479K. The position accounts for 0.86% of the portfolio, ranked #23.

Oracle Alpha first reported a position in VRTX in Q4 2023 and has held it in 2 quarters since. 1,494 funds tracked by Wall St. Rank hold VRTX as of Q1 2024.

  • Oracle Alpha held 1,147 shares of Vertex Pharmaceuticals worth $479K as of Q1 2024.
  • Oracle Alpha bought 277 Vertex Pharmaceuticals shares in Q1 2024, an estimated $117K.
  • Vertex Pharmaceuticals made up 0.86% of Oracle Alpha's portfolio in Q1 2024, its #23 holding.
  • Oracle Alpha first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 2 quarters since.
  • 1,494 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2024.

Based on Oracle Alpha's 13F filing for Q1 2024, filed 15 May 2024.